What is the treatment for stiff person syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Stiff Person Syndrome

Benzodiazepines, specifically diazepam, are the first-line treatment for stiff person syndrome, followed by additional GABAergic agents if symptoms persist, with immunotherapy reserved for refractory cases. 1, 2

First-Line Pharmacological Treatment

Start with diazepam as the primary medication, as it is FDA-approved for stiff-man syndrome and acts as a GABAergic agonist to reduce muscle rigidity and spasms. 1 The FDA label specifically indicates diazepam for relief of skeletal muscle spasm in stiff-man syndrome, making it the evidence-based initial choice. 1

If symptoms persist on benzodiazepines alone, add levetiracetam or pregabalin as adjunctive GABAergic therapy. 2 Pregabalin at 150 mg three times daily has shown satisfying response in clinical cases. 3

Second-Line Treatment

For patients with inadequate response to first-line GABAergic therapy, oral baclofen is recommended over rituximab and tacrolimus. 2 Baclofen provides additional GABAergic modulation and can be titrated for effect. 2

If oral baclofen proves insufficient, rituximab should be considered over tacrolimus as the preferred immunotherapy option. 2

Refractory Disease Management

For treatment-resistant cases, three options exist with varying efficacy:

  • Intrathecal baclofen is more effective than plasmapheresis for refractory symptoms, delivering GABAergic therapy directly to the central nervous system. 2
  • Intravenous immunoglobulin (IVIG) is more effective than plasmapheresis and addresses the autoimmune pathophysiology associated with anti-GAD65 antibodies. 2, 4
  • Plasmapheresis can be used but is less effective than the above options. 2, 5

Propofol may serve as temporary bridge therapy before establishing permanent treatment in severe cases. 2

Immunotherapy Considerations

Early immunotherapy should be strongly considered given the association with autoimmune diseases, particularly in patients with elevated anti-GAD65 antibodies. 6 The autoimmune pathogenesis supports this approach, especially when anti-GAD antibodies are detected. 3

Steroids, plasmapheresis, and IVIG all have roles in the immunotherapy armamentarium. 4 In paraneoplastic variants (associated with breast, colon, or lung cancer), tumor excision combined with plasmapheresis shows significant improvement. 5

Rehabilitation and Physical Therapy

Institute physical therapy early to prevent joint contractures and muscle atrophy from disuse, incorporating both stretching and strengthening activities. 7 Exercise has downstream effects in improving muscle function and reducing inflammation. 7

Therapeutic exercises should specifically target trunk and proximal limb stiffness to improve balance and functionality. 8 Outcome measures demonstrate improvement in muscle flexibility, balance, and functional abilities with structured rehabilitation programs. 8

Avoid splinting, as it increases attention to affected areas, promotes accessory muscle use, causes immobilization leading to muscle deconditioning, and increases risk of learned non-use and pain. 7

Diagnostic Confirmation

Before initiating treatment, confirm diagnosis with:

  • Anti-GAD65 antibody testing (high titers strongly support diagnosis). 3, 5
  • Electromyography showing continuous motor unit activity in agonist and antagonist muscles. 3
  • Exclusion of peripheral neuropathy, radiculopathy, or other movement disorders through thorough neurological examination. 6

Common Pitfalls

The most critical pitfall is misdiagnosis as a psychiatric illness, which can delay appropriate treatment by years. 3 Patients may develop secondary phobic symptoms and adrenergic manifestations (profuse sweating, tachycardia, hypertension) that can mislead clinicians toward psychiatric diagnoses. 3 Maintain high clinical suspicion when patients present with progressive muscle stiffness and painful spasms, particularly when psychiatric treatments fail to improve symptoms. 3

Complete immobilization must be avoided, as strength loss is most dramatic during the first week of immobilization. 7 Instead, implement relative rest combined with eccentric strengthening exercises. 7

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.